MacroGenics Announces Pausing of Enrollment of New Study Participants in LINNET TrialGlobeNewsWire • 02/23/26
MacroGenics Reports Third Quarter 2025 Financial Results and Provides Update on Corporate ProgressGlobeNewsWire • 11/12/25
MacroGenics (MGNX) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?Zacks Investment Research • 11/10/25
MacroGenics to Present at H.C. Wainwright 27th Annual Global Investment ConferenceGlobeNewsWire • 09/02/25
MacroGenics Reports Second Quarter 2025 Financial Results and Highlights Key Strategic PrioritiesGlobeNewsWire • 08/14/25
MacroGenics and Sagard Healthcare Partners Enter into ZYNYZ® Royalty Purchase AgreementGlobeNewsWire • 06/10/25
MacroGenics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference 2025GlobeNewsWire • 06/03/25
MacroGenics Provides Update on Corporate Progress and First Quarter 2025 Financial ResultsGlobeNewsWire • 05/13/25
MacroGenics (MGNX) Loses -48.74% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerZacks Investment Research • 04/03/25
MacroGenics (MGNX) Q4 Earnings: How Key Metrics Compare to Wall Street EstimatesZacks Investment Research • 03/21/25
MacroGenics Announces Date of Fourth Quarter and Full Year 2024 Financial Results Conference CallGlobeNewsWire • 03/06/25
MGNX ALERT: Bragar Eagel & Squire, P.C. is Investigating Macrogenics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the FirmGlobeNewsWire • 12/11/24